Israeli white blood cell biotech Macrocure sets terms for $75 million IPO


Shutterstock photo

Macrocure, a late-stage Israeli biotech developing white blood cell injections to treat hard-to-heal wounds, announced terms for its IPO on Friday. The Petach Tikva, Israel-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, it would command a fully diluted market value of $264 million.

Another Israeli biotech targeting severe burns and hard-to-heal wounds, MediWound ( MDWD ), went public in March.

Macrocure, which was founded in 2008, plans to list on the NASDAQ under the symbol MCUR. Credit Suisse and Jefferies are the joint bookrunners on the deal. It is expected to price during the week of July 28, 2014.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs
More Headlines for: MDWD , MCUR

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by